Vorinostat (HDAC2 inhibitor) and aminocaproic acid (PLAT inhibitor) both inhibited a SARS-CoV2 ‘prey protein’ and targeted a gene within the pathways in cancer and extracellular matrix (ECM)/ECM-associated proteins PES pathways, respectively. The gene discussed is HDAC2; the disease is cancer.